As of the latest Form 4 filed Jun 29, 2026.
What ACADIA Pharmaceuticals Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 42 most recent filings for ACAD.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-29 | 2026-06-26 | Kihara James PRINCIPAL ACCOUNTING OFFICER | SSale | −11.4K | $26.08 | $298K | Yes (planned) | Form 4 ↗ |
| 2026-06-02 | 2026-05-29 | BAKER BROS. ADVISORS LP Director | AAward | +18.6K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-02 | 2026-05-29 | BAKER BROS. ADVISORS LP, Director | AAward | +18.6K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-01 | 2026-05-29 | Ndu Adora Director | MExercise | +8.11K | — | — | No | Form 4 ↗ |
| 2026-06-01 | 2026-05-29 | GAROFALO ELIZABETH A. Director | MExercise | +8.11K | — | — | No | Form 4 ↗ |
| 2026-06-01 | 2026-05-29 | Poole Jonathan Director | MExercise | +2.01K | — | — | No | Form 4 ↗ |
| 2026-06-01 | 2026-05-29 | Daly James M Director | MExercise | +8.11K | — | — | No | Form 4 ↗ |
| 2026-06-01 | 2026-05-29 | Brege Laura Director | MExercise | +8.11K | — | — | No | Form 4 ↗ |
| 2026-06-01 | 2026-05-29 | HARRIGAN EDMUND Director | MExercise | +8.11K | — | — | No | Form 4 ↗ |
| 2026-05-27 | 2026-05-26 | Kihara James PRINCIPAL ACCOUNTING OFFICER | SSale | −5.40K | $21.18 | $114K | No | Form 4 ↗ |
| 2026-05-05 | 2026-05-04 | Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER | SSale | −3.51K | $21.79 | $76.4K | No | Form 4 ↗ |
| 2026-05-05 | 2026-05-04 | Kihara James PRINCIPAL ACCOUNTING OFFICER | SSale | −1.33K | $21.79 | $29.0K | No | Form 4 ↗ |
| 2026-05-05 | 2026-05-01 | Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER | MExercise | +6.82K | — | — | No | Form 4 ↗ |
| 2026-05-05 | 2026-05-01 | Kihara James PRINCIPAL ACCOUNTING OFFICER | MExercise | +2.60K | — | — | No | Form 4 ↗ |
| 2026-04-07 | 2026-04-07 | Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER | SSale | −2.71K | $22.20 | $60.1K | No | Form 4 ↗ |
| 2026-04-07 | 2026-04-07 | Kihara James PRINCIPAL ACCOUNTING OFFICER | SSale | −1.03K | $22.20 | $22.9K | No | Form 4 ↗ |
| 2026-04-07 | 2026-04-05 | Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER | MExercise | +5.28K | — | — | No | Form 4 ↗ |
| 2026-04-07 | 2026-04-05 | Kihara James PRINCIPAL ACCOUNTING OFFICER | MExercise | +2.01K | — | — | No | Form 4 ↗ |
| 2026-03-26 | 2026-03-26 | Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER | SSale | −37.00 | $21.72 | $803.54 | No | Form 4 ↗ |
| 2026-03-26 | 2026-03-26 | Schneyer Mark C., EVP, CHIEF FINANCIAL OFFICER | SSale | −3.17K | $21.65 | $68.7K | No | Form 4 ↗ |
| 2026-03-26 | 2026-03-26 | Kihara James PRINCIPAL ACCOUNTING OFFICER | SSale | −12.00 | $21.73 | $260.70 | No | Form 4 ↗ |
| 2026-03-26 | 2026-03-26 | Kihara James, PRINCIPAL ACCOUNTING OFFICER | SSale | −1.10K | $21.65 | $23.8K | No | Form 4 ↗ |
| 2026-03-26 | 2026-03-25 | Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER | MExercise | +6.18K | — | — | No | Form 4 ↗ |
| 2026-03-26 | 2026-03-25 | Schneyer Mark C., EVP, CHIEF FINANCIAL OFFICER | SSale | −4.18K | $21.47 | $89.7K | No | Form 4 ↗ |
| 2026-03-26 | 2026-03-25 | Thompson Elizabeth H.Z. EVP, Head of Research & Dev | SSale | −3.44K | $21.47 | $73.7K | No | Form 4 ↗ |
| 2026-03-26 | 2026-03-25 | Owen Adams Catherine Chief Executive Officer | SSale | −11.6K | $21.47 | $250K | No | Form 4 ↗ |
| 2026-03-26 | 2026-03-25 | Kihara James PRINCIPAL ACCOUNTING OFFICER | MExercise | +2.14K | — | — | No | Form 4 ↗ |
| 2026-03-26 | 2026-03-25 | Kihara James, PRINCIPAL ACCOUNTING OFFICER | SSale | −833.00 | $21.47 | $17.9K | No | Form 4 ↗ |
| 2026-03-26 | 2026-03-25 | Rhodes Jennifer J EVP, CHIEF LEGAL OFFICER, SEC | SSale | −3.84K | $21.47 | $82.5K | No | Form 4 ↗ |
| 2026-03-26 | 2026-03-24 | Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER | MExercise | +8.14K | — | — | No | Form 4 ↗ |
| 2026-03-26 | 2026-03-24 | Thompson Elizabeth H.Z. EVP, Head of Research & Dev | MExercise | +6.71K | — | — | No | Form 4 ↗ |
| 2026-03-26 | 2026-03-24 | Owen Adams Catherine Chief Executive Officer | MExercise | +23.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-26 | 2026-03-24 | Kihara James PRINCIPAL ACCOUNTING OFFICER | MExercise | +1.63K | — | — | No | Form 4 ↗ |
| 2026-03-26 | 2026-03-24 | Rhodes Jennifer J EVP, CHIEF LEGAL OFFICER, SEC | MExercise | +7.51K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2024-05-03 | 2024-05-02 | Teehan Brendan EVP, COO, HEAD OF COMMERCIAL | SSale | −3.48K | $16.94 | $58.9K | No | Form 4 ↗ |
| 2024-05-03 | 2024-05-02 | DAVIS STEPHEN CEO | SSale | −11.4K | $16.94 | $194K | No | Form 4 ↗ |
| 2024-05-03 | 2024-05-02 | Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER | SSale | −3.50K | $16.94 | $59.3K | No | Form 4 ↗ |
| 2024-05-03 | 2024-05-02 | Kihara James PRINCIPAL ACCOUNTING OFFICER | SSale | −1.33K | $16.94 | $22.5K | No | Form 4 ↗ |
| 2024-05-03 | 2024-05-01 | Teehan Brendan EVP, COO, HEAD OF COMMERCIAL | MExercise | +6.81K | — | — | No | Form 4 ↗ |
| 2024-05-03 | 2024-05-01 | DAVIS STEPHEN CEO | MExercise | +22.4K | — | — | No | Form 4 ↗ |
| 2024-05-03 | 2024-05-01 | Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER | MExercise | +6.81K | — | — | No | Form 4 ↗ |
| 2024-05-03 | 2024-05-01 | Kihara James PRINCIPAL ACCOUNTING OFFICER | MExercise | +2.60K | — | — | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also ACAD’s full analysis or the market-wide insider trading feed. The tabs above jump to ACAD’s other SEC data.
Source: SEC Form 4 filings for ACAD, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.